baber/WOPTO huggingface dataset:
Patent AU-671282-B2 (AU)
Title: Cellular system
Inventor: POEYHOENEN PETRI
IPC: H04W16/12
Filed: 1993-05-06
Granted: 1996-08-22
Abstract: PCT No. PCT/FI93/00195 Sec. 371 Date Feb. 17, 1995 Sec. 102(e) Date Feb. 17, 1995 PCT Filed May 6, 1993 PCT Pub. No. WO93/22849 PCT Pub. Date Nov. 11, 1993A digital TDMA/FDMA (Time Division Multiple Access/Frequency division Multiple Access) cellular network system, suitable for a microcellular network and to maximize the advantage to be gained from interference diversity, including base stations forming radio cells, each having a determined static frequency of a channel of the cell and including a first transceiver continuously transmitting control data of the system concerning the cell at the control channel frequency, at least in one predetermined time slot of a TDMA frame. The TDMA frame of the first transceiver includes traffic channels at least in a part of the other time slots. Each base station further includes at least one second transceiver for the traffic channels. The system further includes mobile stations connected to the base stations via a radio path. The traffic channels of the second transceiver units use frequency-hopping, at least in a part of the radio cells, in such a way that, on those traffic channels aligned with the predetermined time slots of the control data of the cell in the first transceiver, substantially all frequencies of the available frequency band, except the control data transmission frequency determined for the cell, belong to the hopping sequence. On those traffic channels which are in the other time slots, substantially all frequencies of the available frequency band belong to the hopping sequence.
Patent AU-714339-B2 (AU)
Title: Blade shape
Inventor: COX JUAN EDUARDO FERNANDEZ
IPC: A01D34/73
Filed: 1995-12-27
Granted: 1999-12-23
Abstract: PCT No. PCT/EP95/05136 Sec. 371 Date Jun. 27, 1997 Sec. 102(e) Date Jun. 27, 1997 PCT Filed Dec. 27, 1995 PCT Pub. No. WO96/20585 PCT Pub. Date Jul. 11, 1996The sharpness or efficiency of cutting edges of blade rails or other blades used in mowing mechanisms is very rapidly lost on meeting a obstacle. The blade shape of this invention, presents a cutting edge including a series of adjacent parallel recesses transversely to the cutting edge on the top of the blade. This gives equidistant thin and complete material. A differentiation is made on the cutting edge between the protective material (full thickness) and sharp edges (recesses). Experience has shown that, on the encountering of an obstacle, the cutting edge (thin Material) is protected by the full material to its left and right which results in a long useful life with relatively constant cutting efficiency.
Patent AU-776686-B2 (AU)
Title: Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
Inventor: EL-RASHIDY RAGAB
IPC: A61K9/00
Filed: 1999-06-22
Granted: 2004-09-16
Abstract: Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea symptoms associated with the use of apomorphine.
Patent AU-683421-B2 (AU)
Title: Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
Inventor: COHEN IRUN R
IPC: C07K14/725
Filed: 1993-07-28
Granted: 1997-11-13
Abstract: The invention relates to conjugates of poorly immunogenic antigens, e.g. peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of human heat shock protein hsp65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are Pep278h, which corresponds to positions 458-474 of human hsp65, and Pep II, which corresponds to positions 437-448 of human hsp65, but in which two cysteine residues at positions 442 and 447 are replaced serine residues.
Patent AU-755690-B2 (AU)
Title: Method of authenticating information, disk playback apparatus, and entertainment apparatus
Inventor: NODA SHINJI
IPC: A63F13/73
Filed: 1999-09-16
Granted: 2002-12-19
Abstract: A playback instructing unit (108) in a disk playback controller (28) has a function to instruct a CPU (42) to play back an optical disk (12) at different access positions in an absolute authentication process and an arbitrary authentication process. An absolute decision unit (110) has a function to be activated by an absolute authentication instruction from the playback instructing unit (108) and authenticate the decided result from an authentication decision means (106) according to a first rule (which declares normal authentication based on a normal decision). An arbitrary decision unit (112) has a function to be activated by an arbitrary authentication instruction from the playback instructing unit (108) and authenticate the decided result from the authentication decision unit (106) according to a second rule (which declares normal authentication based on an abnormal decision). Even if a special device which can normally authenticate an optical disk (12) that should not be authenticated normally is connected to a disk access mechanism (14), the optical disk (12) that should not be authenticated normally or the special device can reliably be detected to forcibly interrupt any process being carried out, so that the optical disk (12) can effectively be prevented from being illegally copied. <IMAGE>
Patent AU-694326-B2 (AU)
Title: Method and apparatus for separating non-soluble particles from a liquid
Inventor: DUFOUR RENEAU
IPC: B01D17/035
Filed: 1996-03-20
Granted: 1998-07-16
Abstract: Disclosed is a clarifier for use in treating a liquid containing non-soluble particles in suspension in order to separate these particles from the liquid. It comprises a tank, a liquid supply duct opening into the bottom portion of the tank and an injector for injecting a gas under pressure into at least part of liquid supplied to the supply duct in order to saturate this liquid with said gas and thus to generate gas bubbles as the saturated liquid is subject to depressurization within the tank. The gas bubbles that are so-generated adhere to the particles in suspension in the liquid and lift them up to form a floating layer of sludge in the top portion of the tank. A scraper is provided in the top portion of the tank for skimming off the layer of sludge while it is formed. A plurality of plates extend at an angle within the tank above the supply duct. These plates define a set of upwardly inclined channels each having an upper end that is opened and through which the liquid fed into the tank may enter the channel. A liquid outlet mounted within the lower end of each channel to collect and remove from the tank the liquid that has been treated within the same. Thanks to its shape and structure, this clarifier occupies a surface area on the ground that is 50% or less smaller than any known clarifier of the same capacity. Its structure also permits to maintain much more microbubbles of requested size for a same amount of injected air in order to increase the probability of contact between the particles and the air bubbles.
Patent AU-733284-B2 (AU)
Title: Nasal and ocular administration of ketamine to manage pain and for detoxification
Inventor: WEG STUART L
IPC: A61K31/137
Filed: 1996-02-14
Granted: 2001-05-10
Abstract: The present invention relates to facilitating detoxification and treatment of substance addiction. Accordingly, the present invention is broadly directed to a method for treating substance addiction subject comprising administering ketamine in an amount effective to facilitate detoxification or assist in overcoming substance addiction, or both. The present invention is broadly directed to transmucosal administration of ketamine. In a further embodiment, the present invention provides for parenteral administration of ketamine. Treatment with ketamine advantageously allows for patient self administration of the drug, which provides for management or treatment of a substance addiction on an outpatient basis. Moreover, ketamine administration in nasal sprays and inhalers are generally socially acceptable. In a specific example, a dedicated smoker was able to reduce her craving from three packs of ciga rettes a day.
Patent AU-744321-B2 (AU)
Title: Apparatus dispensing wiping material in a front position of the reel
Inventor: GRANGER MAURICE
IPC: B65D25/52
Filed: 1999-08-03
Granted: 2002-02-21
Abstract: A dispensing machine for wipe material with the reel in a frontal position of the type includes a housing (2), a cover (3), a drum (4), a cutting device (5-6) built into the drum, a cam and start sprig for starting and returning the drum and a device to prevent loops in the material paid out from the reel (B) of material. The device includes a reel holder (16) capable of engaging and positioning itself on a fixed support (17) physically joined to the rear wall of the bottom of the housing, said reel holder being rotatably mounted on support (17) in opposition to a spring and in that the reel holder is devised to position itself on a long bearing surface (17b) of support (17), being locked into position relative to the latter and in that the reel holder co-operates with the core or spindle of the reel of wipe material in order to drive it.
Patent AU-627285-B2 (AU)
Title: Derivatives of n-phenylbenzamide with anti-ulcer and anti-allergy activity and a method for their preparation
Inventor: MAKOVEC FRANCESCO
IPC: C07C255/57
Filed: 1990-02-19
Granted: 1992-08-20
Abstract: PCT No. PCT/EP90/00270 Sec. 371 Date Aug. 19, 1991 Sec. 102(e) Date Aug. 19, 1991 PCT Filed Feb. 19, 1990 PCT Pub. No. WO90/09989 PCT Pub. Date Sep. 7, 1990.Derivatives of N-phenylbenzamide with general formula (1) in which R1 is a cyano, nitro, halogen, hydrozy, C1-C4 alkyl methyl, methoxy or tetrazol-5-yl group, R2 is hydrogen, hydroxy, or methoxy, R3 is a tetrazol-5-yl group or hydrogen, R4 and R5 are hydrogen if R3 is tetrazolyl but are independently selected from the group consisting of carboxy, methoxycarbonyl, ethoxycarbonyl and carbamoyl if R3 is hydrogen, and R6 is hydrogen or methyl. The derivatives have an anti-ulcer and anti-allergy activity.
Patent AU-666994-B2 (AU)
Title: Stressing anchorage for at least one tension element running inside an encasing tube and method of producing the stressing anchorage
Inventor: LUTHI KURT
IPC: E02D5/74
Filed: 1994-01-11
Granted: 1996-02-29
Abstract: In the case of a stressing anchorage means for tension elements (3) running within a sheath, an anchor plate (8) having a circular opening (9) is laid on an outer wall (41) of a structural part (1). A region, of the opening, which is remote from the structural part exhibits a cone (10) which opens outwards. A plastic trumpet (12) is welded, at its end located in the structural part, to the sheath, which likewise consists of plastic. The outer end of the trumpet is approximately flush with that end side of the anchor plate which is remote from the structural part. An intermediate piece (16) projects into the trumpet by means of a protrusion (17), the outer casing surface of which is configured as a truncated cone (18). By means of the truncated cone, the outer end of the trumpet is pressed against the cone of the anchor plate and fixed in an annular gap between said truncated cone and said cone once the anchor bush has been positioned on the intermediate piece and the stressing strands (4) of the individual tension elements have been prestressed and are retained by the clamping wedges (15). The fact that, during the production of the stressing anchorage means, first of all the inner end of the trumpet is welded to the sheath and the outer end of the trumpet projects out of the structural part, and is only cut back to the necessary length when the stressing anchorage means is fitted, results in the convenient compensation of length tolerances in a transition zone between structure and stressing cable and/or between the sheath end and the outer wall of the structure. One embodiment variant shows a correspondingly constructed, electrically insulated stressing anchorage means. <IMAGE>
Patent AU-679700-B2 (AU)
Title: Dry powder inhaler
Inventor: MECIKALSKI MARK BERNARD
IPC: A61M15/00
Filed: 1993-10-12
Granted: 1997-07-10
Abstract: A dry powder medicine inhaler has an impeller non-concentrically disposed in a mixing chamber. A motor spins the impeller at high speed. A plunger introduces a dose of powdered medicine into the chamber so that all powder particles are available for intermixing disaggregation and comminution. An aperture receives a first stream of air and passes it towards the mouthpiece for inhalation by the user. A wall has at least one aperture for diverting a portion of a main air stream into the aerosolizing chamber to mix with the particles to form a fine, low-density, low velocity, dry mist of powdered medicine for inhalation by the user.
Patent AU-671695-B2 (AU)
Title: New preparation process for 6alpha,9alpha-difluorinated steroids and new intermediates
Inventor: GODARD JEAN-YVES
IPC: C07J3/00
Filed: 1994-02-04
Granted: 1996-09-05
Abstract: The invention relates to a process for preparing the compounds (I):   <IMAGE> where R is hydrogen or an ester residue, starting with the compound (II): <IMAGE> by oxidative degradation, then fluorination in 6 and hydrofluorination of the epoxide. The compounds (I) are known in particular as anti-inflammatory agents.
Patent AU-740950-B2 (AU)
Title: Preparation of collagen
Inventor: GUNASEKARAN SUBRAMANIAN
IPC: A61K38/17
Filed: 1998-01-12
Granted: 2001-11-15
Abstract: Purified collagen is produced by a method containing steps of contacting a collagen sample with a first proteolytic enzyme followed by contacting with a reducing agent and a second proteolytic enzyme. Preferably, the first and second proteolytic enzymes are papain and the reducing agent is sodium sulfide, dithiothreitol, glutathionine or sodium borohydride. A biocompatible collagen is prepared by contacting the purified collagen with a delipidation agent such as chloroform or methanol to produce delipidated collagen, and then contacting the delipidated collagen with a phosphorylation agent such as sodium trimetaphosphate. Prior to phosphorylation, the delipidated collagen may be treated by compressing, dehydrating, dispersing and drying to form collagen fibers. Also, prior to phosphorylation, the delipidated collagen may be treated by filter-sterilizing. De-epithelializing of the collagen may carried out prior to treating with the first proteolytic enzyme. The purified and biocompatible collagen may be used in transplantation or hemostasis, and may be provided with compounds such as antimicrobials, antivirals, growth factors and other compounds suitable for biomedical use.
Patent AU-720017-B2 (AU)
Title: 1,3,5-triazine derivative salt of a polyacid comprising phosphorus, sulfur and oxygen and process for its production
Inventor: SUZUKI KEITARO
IPC: C08K5/3492
Filed: 1998-02-26
Granted: 2000-05-18
Abstract: A 1,3,5-triazine derivative salt of a polyacid comprising phosphorus, sulfur and oxygen, which has a solubility of from 0.01 to 0.10 g/100 ml in water (25 DEG C) and a pH of from 2.0 to 7.0 as a 10 wt% aqueous slurry (25 DEG C), and which is obtained from the following steps (a) and (b):   (a) a step of obtaining a reaction product by mixing melamine, phosphoric acid and sulfuric acid at a temperature of from 0 to 330 DEG C in such ratios that the melamine is from 1.0 to 4.0 mols per mol of the total molar amount of the phosphoric acid (as calculated as orthophosphoric acid content) and the sulfuric acid (as sulfuric acid content), and the sulfuric acid (as sulfuric acid content) is from 0.05 to 20 mols per mol of the phosphoric acid (as calculated as orthophosphoric acid content), and (b) a step of baking the reaction product obtained in step (a) at a temperature of from 340 to 400 DEG C for from 0.1 to 30 hours; and a process for its production.
Patent AU-634569-B2 (AU)
Title: New omegaphenylamino alkanoic acids substituted on the aromatic nucleus by a radical derived from 19-nor steroids, their salts, their preparation process and the new intermediates of this process, their use as medicaments and the compositions containing them
IPC: C07J1/00
Filed: 1990-08-22
Granted: 1993-02-25
Abstract: New products (I): 
<IMAGE>
 in which R1 denotes an aliphatic hydrocarbon radical (C1-8), Ra and Rb denote a hydrogen or an alkyl (C1-4), R2 denotes a hydrogen or an optionally substituted alkyl (C1-12), n denotes one of the values from 1 to 6, Z denotes a carboxyl group which is free or converted into salt in the form of an alkali metal or alkaline-earth metal, ammonium or amine salt, X denotes the residue of an optionally substituted pentagonal or hexagonal ring optionally carrying an unsaturation, and the wavy line in position 13 means that R1 may be in an alpha or beta position, their salts, process for their preparation and their application as medications.
Patent AU-531850-B2 (AU)
Title: Dental glass ionomer cements
Inventor: SCHMITT WERNER
IPC: A61K6/884
Filed: 1980-08-13
Granted: 1983-09-08
Abstract: Dental glass ionomer cements are obtained by using as a mixing component for preparing the final cement mixture either a liquid mixing component comprising an aqueous solution of a certain maleic acid-acrylic acid-copolymer and optionally usual additives or a solid, powdery mixing component comprising a powder mixture of a glass ionomer cement powder and the maleic acid-acrylic acid-copolymer in solid form and optionally usual additives.
Patent AU-635971-B2 (AU)
Title: Personal computer memory bank parity error indicator
IPC: G06F12/16
Filed: 1990-10-08
Granted: 1993-04-08
Abstract: A personal computer has two memory banks (12,14) respectively connected to two parity check units (16,18) operative to detect parity errors. Upon doing so, each unit (16,18) feeds a parity error signal to a separate latch (22,24). The latches (22,24) are connected to a logic circuit (26) which is in turn connected to an interrupt controller (34) that initiates an interrupt (36) when a parity error occurs. One latch (22) is further connected to a check bit (41) of a register (40) of an I/O port (38) and the check bit (41) is set by the one latch (22). An interrupt handler reads the register and provides messages indicating which memory bank (12,14) caused the parity error.
Patent AU-628679-B2 (AU)
Title: Apparatus for counting and determining at least one leucocytic sub-population
Inventor: CHAMPSEIX SERGE
IPC: G01N15/12
Filed: 1990-10-26
Granted: 1992-09-17
Abstract: A housing (1), for the injection of a flow of sample which is to be analysed inside a measuring cell (5) through which a light beam (24) passes, contains inner (16) and outer (10) nozzles enabling the sample to be forced into a stream by a liquid under pressure. Electrodes for the measurement of resistivity of the leucocyte subpopulation are constituent components (8, 16) of the injection housing. Units for collection and processing of the signals provided by the optical sensor and the electrodes are also provided. Application to blood analysis. 
<IMAGE>
Patent AU-646822-B2 (AU)
Title: Erythropoietin isoforms
Inventor: STRICKLAND THOMAS WAYNE
IPC: C12N5/00
Filed: 1990-10-09
Granted: 1994-03-10
Abstract: Continuation in part of U.S. application no. 421,444 filed 13 October 1989. Erythropoietin isoforms claimed are produced by expression of exogenous DNA in a non-human eukaryotic host cell. They contain amino acids 1-165 or 1-166 of natural human erythropoietin. The isoforms pref. contain 1-14 sialic acid gps. (esp. 9-14 gps.) per erythropoietin molecule. Use of the isoforms and their mixts. are also claimed comprising subjecting a purified erythropoietin to isoelectric focussing and eluting a single isoform from the gel. Specifically claimed erythropoietin analogues are (Asn69) EPO,(Asn125,Ser127) EPO,(Thr125) EPO and (Pro124,Thr125) EPO.
Patent AU-684798-B2 (AU)
Title: Regulator of contact-mediated hemolysin
Inventor: KING C HAROLD
IPC: G01N33/569
Filed: 1994-05-24
Granted: 1998-01-08
Abstract: PCT No. PCT/US94/05869 Sec. 371 Date Jun. 26, 1996 Sec. 102(e) Date Jun. 26, 1996 PCT Filed May 24, 1994 PCT Pub. No. WO94/28137 PCT Pub. Date Dec. 8, 1994The present invention relates to a nucleic acid that encodes a hemolysin protein and to a nucleic acid that encodes a positive regulator of hemolysis. The nucleic acid can be the basis of a vaccine against tuberculosis. The nucleic acid can be inserted into an avirulent vaccine strain such as M. bovis BCG.
Patent AU-650258-B2 (AU)
Title: Fiber optic transimpedance receiver
Inventor: KRUSE HERMAN
IPC: H04B10/2507
Filed: 1990-12-03
Granted: 1994-06-16
Abstract: A transimpedance receiver for broad band optical signals, such as carry multichannel CATV signals or broad band data over an optical fiber which may vary in length (e.g. from 2 km to 20 km) such that the optical power at a photodetector of the receiver may vary widely depending upon where the receiver, and is installed in the fiber optic distribution system utilizes a broad band device, preferably a GASFET, the internal capacitance and gain of which enables amplification over the broad band frequency range without oscillation. Different values of transimpedance for converting the current signal from the photodetector into an output voltage at the output (the drain) of the device which is in a range within which the device is linear, and does not introduce distortion into the signal, is obtained by connecting, between the output and the input of the device, a feedback resistor selected from a group consisting of resistors of different value each dependent upon the optical power of the optical signal applied to the photodetector. The output voltage is coupled to an electrical transmission line which may be a low impedance coaxial line using a buffer amplifier incorporating a device of the same type as used in the transimpedance amplifier which has connected thereto networks for controlling the spectral response of the receiver so that it remains essentially flat over the broad band frequency range.
Patent AU-718300-B2 (AU)
Title: Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents
Inventor: ISAKSON PETER C
IPC: A61K31/4433
Filed: 1996-09-27
Granted: 2000-04-13
Abstract: A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in companion animals is disclosed.\!
Patent AU-671045-B2 (AU)
Title: Polyethylene glycols
Inventor: HAKIMI JOHN
IPC: A61K47/42
Filed: 1994-11-01
Granted: 1996-08-08
Abstract: The present invention relates to physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugates having at least part of the biological activity of the protein which forms the conjugate, without exhibiting the same disadvantageous immunogenic responses thereof.
Patent AU-693479-B2 (AU)
Title: Process for producing lignin-containing polymers
Inventor: HUTTERMANN ALOYS
IPC: C08H7/00
Filed: 1994-09-20
Granted: 1998-07-02
Abstract: PCT No. PCT/EP94/03142 Sec. 371 Date Jul. 6, 1995 Sec. 102(e) Date Jul. 6, 1995 PCT Filed Sep. 20, 1994 PCT Pub. No. WO95/08588 PCT Pub. Date Mar. 30, 1995Polymers containing lignin and organic compounds are produced by polymerizing the lignin with organic compounds containing at least 3 carbon atoms as well as oxygen, nitrogen and/or multiple-linkage functions in the presence of radically oxidizing enzymes and of oxidation products constituting their substrate.
Patent AU-679572-B2 (AU)
Title: Use of thiazolidinediones to prevent or delay onset of NIDDM
Inventor: OLEFSKY JERROLD
IPC: A61K31/505
Filed: 1994-09-14
Granted: 1997-07-03
Abstract: A novel method of using thiazolidinedione derivatives and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom is disclosed.